Steven Cohen Biomarin Pharmaceutical Inc Call Options Transaction History

Point72 Asset Management, L.P.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $20.7 Million - $28.2 Million	300,000 New	300,000 $21.1 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $59.3 Million - $74 Million	-798,500 Reduced 90.39%	84,900 $6.55 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $45.6 Million - $53.7 Million	564,400 Added 176.93%	883,400 $78.8 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $25.7 Million - $30.3 Million	319,000	319,000 $29.7 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.